Home > Keywords > Thématique > Science

Science

Articles

  • RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
    15 November 2022, by Elodie DORMES

    Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) — RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC). This radiotracer will serve as a companion diagnostic for future Targeted Alpha Therapy (TAT) for these cancers. 68Ga-RMX-VH is a (…)

  • Harnessing TfR1 for Cross-Species Systemic Delivery of siRNAs to Deep Brain Regions Using Single-Domain Antibodies
    26 May, by Emmanuelle BETTENDORF

    Our latest preprint demonstrating the ability of the VECTrans® platform to deliver therapeutics, particularly oligonucleotides, to deep regions of the brain at clinically viable doses has just been published by bioRxiv.
    The research by @Guillaume Jacquot and the Vect-Horus team details the unique functions of our technology platform to transport oligonucleotides across the blood-brain barrier and open up new avenues for the treatment of diverse central nervous system disorders. (…)

  • Vect-Horus appoints Claudia Fromond as new Director of R&D
    10 March, by Emmanuelle BETTENDORF

    We are very pleased to welcome Claudia Fromond to Vect-Horus as our new Director of R&D.
    Claudia is a highly regarded pharmacology and translational science leader with extensive experience in R&D. She has successfully overseen first-in-class programs from discovery to Investigational New Drug (IND) application and early clinical development, including a portfolio of seven IND-enabling programs which achieved Phase 1/2 readiness.
    “Claudia has a proven track record of successfully (…)

  • Meet Vect-Horus at Deeptech in Glioblastoma Symposium
    13 January, by Emmanuelle BETTENDORF

    Cédric Malicet, our Oncology Program Director, will be taking part in a panel discussion at the DeepTech in Glioblastoma conference, organized by Paris Saclay Cancer Cluster (PSCC), and taking place January 22 in Villejuif, France.
    Cedric will participate in a pitch session entitled “A comprehensive and diverse front against glioblastoma”, along with representatives from Carthera, TheraSonic, Robeauté, Innov’nCare , with the discussion moderated by Professor Ahmed Idbaih .
    It takes place (…)

  • How blood–brain barrier technology is unleashing CNS therapies
    19 September 2025, by Emmanuelle BETTENDORF

    Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
    It’s well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
    It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, (…)

  • Vect-Horus team will attend the 8AIS2020 symposium from Nov. 23-26, 2020
    12 November 2020, by Elodie DORMES

    Marion DAVID will be presenting a poster entitled “Development of versatile single domain antibody vectors that enhance brain deliver of antibodies by targeting the TfR transport system. ”
    Please use the partnering system to contact us and organize a 1&1 meeting : www.aiscongress.com

  • Early September VECT-HORUS’ team will be attending the EANM2023 Annual Congress!
    8 September 2023, by Emmanuelle BETTENDORF

    On this occasion, our partner Radiomedix, Inc. , was selected to present an update of our joint research program. This talk untitled “Glioblastoma and Pancreatic Adenocarcinoma - Versatile radiolabeled probe targeting Low Density Lipoprotein Receptors (LDLR)” will be given Sunday, September 10th between 4:55 PM and 5:05 PM at the Hall E2 by Izabela Tworowska.
    Come and take the opportunity to meet and discuss with Vect-Horus on September 9-13, 2023 in Vienna!
    Our #Oncology team, Cedric (…)

  • Neurotensin, vectorised by VECT-HORUS, is the first drug-candidate in neuroprotective hypothermia
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS starts the regulatory preclinical development of VH-N439, positioned as a first-in-class neuroprotective agent in brain ischemia Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the brain, but unable to cross the blood-brain barrier (BBB) when administrated alone systemically. The Company has developed VH-N439, a new chemical entity based on the conjugation of one of its peptide-vectors to an analogue of neurotensin.
    Using in vivo (…)

  • Vect-Horus will be attending the #EANM 2022 Annual Congress
    18 October 2022, by Elodie DORMES

    Great occasion to assist to valuable conferences about Nuclear Medicine, Molecular Imaging, Optimization of Radiolabeled Biomolecules in one of the most valuable Nuclear Medicine event in Europe.
    Meet with Cedric MALICET, PhD during the EANM on Oct 15-19, 2022 in Barcelona.

  • Meet Vect-Horus at TIDES Europe in Vienna from November 16th to 18th, 2022.
    16 November 2022, by Elodie DORMES

    Guillaume JACQUOT will share a presentation on “Targeted delivery of Therapeutic Oligonucleotides to CNS by systemic administration” a good opportunity for Vect-Horus to present its last results.
    Emmanuelle BETTENDORF will be there as well to assist to conferences about Emerging #Oligonuleotide Therapeutics, #Delivery Strategies for Oligonucleotides, Peptides and mRNA and meet with all actors in the field.